ALX Oncology is a technology company.
ALX Oncology has raised $146.0M across 2 funding rounds.
ALX Oncology has raised $146.0M in total across 2 funding rounds.
ALX Oncology has raised $146.0M in total across 2 funding rounds.
ALX Oncology's investors include BigSpring, Earlybird Venture Capital, Mohr Davidow Ventures, Morgenthaler Ventures, Carol Gallagher, venBio, Versant Ventures, Vivo Capital.
ALX Oncology is a publicly traded, clinical-stage biopharmaceutical company focused on developing therapies that harness the immune system to treat cancer, particularly through CD47 blockade.[1][3][4] Its lead candidate, evorpacept, is a differentiated CD47 inhibitor designed to minimize toxicities while enhancing immune response against tumors, showing improved response rates in trials like ASPEN-06 for HER2+ gastric cancer and advancing across solid tumors and hematologic cancers in combination therapies.[1][2][4] The company serves cancer patients with advanced malignancies, solving the problem of immune evasion by cancer cells via CD47 signaling, with over 700 patients treated to date and a new pipeline addition, ALX2004, an EGFR-targeted antibody-drug conjugate (ADC) cleared for Phase 1 trials in mid-2025.[3][5] Growth momentum includes robust clinical data, multiple ongoing trials, and expansion into ADCs via proprietary platforms.[1][3][6]
ALX Oncology was founded to pioneer highly differentiated immuno-oncology medicines, starting with evorpacept (previously ALX148) as a next-generation CD47 blocker—a fusion protein of SIRPα and an inactive Fc region to avoid prior agents' toxicities.[1][2] Emerging from extensive preclinical research validating CD47's role in cancer immune evasion, the company gained early traction through Phase 1/2 trials enrolling over 700 patients, demonstrating tolerability and efficacy signals across tumor types.[1][4] Key pivots include broadening evorpacept's combinations with standard therapies and, in March 2025, introducing ALX2004 from its linker-payload platform for EGFR-expressing solid tumors, marking entry into ADCs.[3][5] Backed by investors like Foresite Capital, ALX has evolved from a CD47-focused biotech to a pipeline immuno-oncology player headquartered in South San Francisco.[2][3]
ALX Oncology rides the immuno-oncology wave, capitalizing on CD47 as a myeloid checkpoint exploited by >80% of cancers to dodge phagocytosis, amid surging demand for combination therapies post-PD-1/PD-L1 successes.[1][2] Timing aligns with ADC resurgence (e.g., ALX2004) and immune synergy needs, fueled by market forces like rising solid tumor incidence and FDA nods for CD47 combos.[3][5] By validating evorpacept's safety in large cohorts, ALX influences standards of care, potentially enabling "cornerstone" roles in regimens and accelerating CD47/ADC adoption in the $100B+ oncology market.[1][4]
ALX Oncology's path forward hinges on evorpacept readouts from Phase 2/3 trials and ALX2004's Phase 1 data in 2026, with potential partnerships amplifying combos amid immuno-oncology maturation.[1][3][6] Trends like multi-checkpoint inhibition and ADC-linker advances will shape it, possibly evolving ALX into a multi-asset leader if efficacy holds. This positions them to deliver on cancer's immune promise, transforming evorpacept from differentiated asset to ecosystem cornerstone.[1][4]
ALX Oncology has raised $146.0M across 2 funding rounds. Most recently, it raised $110.0M Series C in February 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2020 | $110.0M Series C | BigSpring, Earlybird Venture Capital, Mohr Davidow Ventures, Morgenthaler Ventures, Carol Gallagher, venBio, Versant Ventures, Vivo Capital | |
| Mar 1, 2015 | $36.0M Series A | BigSpring, Mohr Davidow Ventures, Morgenthaler Ventures, Carol Gallagher, venBio |